NervGen Pharma Corp.
NGENF
$2.17
$0.01820.85%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -6.15M | -3.83M | -5.72M | -1.74M | -6.33M |
| Total Depreciation and Amortization | 11.30K | 10.70K | 11.00K | 28.40K | 28.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.99M | -34.50K | 2.35M | -827.00K | 3.81M |
| Change in Net Operating Assets | 531.00K | -363.00K | 303.70K | 129.70K | 215.80K |
| Cash from Operations | -2.61M | -4.22M | -3.06M | -2.41M | -2.27M |
| Capital Expenditure | -- | -- | -- | -- | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.00K | 18.50K | 6.10K | -- | 0.00 |
| Cash from Investing | 18.00K | 18.50K | 6.10K | -- | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.20K | -25.20K | -25.20K | -25.20K | -25.20K |
| Issuance of Common Stock | 335.20K | 295.00K | 164.00K | 23.63M | 100.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -27.40K | -1.60M | -- |
| Cash from Financing | 221.50K | 197.80K | 81.30K | 16.32M | 55.00K |
| Foreign Exchange rate Adjustments | -297.30K | -68.60K | 231.70K | -83.30K | -84.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.67M | -4.07M | -2.74M | 13.83M | -2.30M |